A Multi-Institutional Retrospective Analysis of Toceranib Phosphate for Presumed or Confirmed Canine Aortic Body Chemodectomas
| Autor: | Melissa A. Tropf, Jessica L. Ward, Giovanna M Coto, Yeon-Jung Seo, Chad M Johannes, Jonathan P. Mochel, Margaret L. Musser |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Toceranib Phosphate Multivariate analysis Toceranib pericardiectomy 040301 veterinary sciences medicine.medical_treatment chemotherapy 0403 veterinary science 03 medical and health sciences 0302 clinical medicine medicine Pericardiectomy Chemodectoma Prospective cohort study heart base tumor Original Research Chemotherapy lcsh:Veterinary medicine General Veterinary Palladia business.industry 04 agricultural and veterinary sciences radiation 030220 oncology & carcinogenesis dog lcsh:SF600-1100 Veterinary Science Radiology business Aortic body medicine.drug |
| Zdroj: | Frontiers in Veterinary Science Frontiers in Veterinary Science, Vol 8 (2021) |
| ISSN: | 2297-1769 |
| Popis: | Aortic body tumors, specifically chemodectomas, are the second most common type of canine cardiac tumor; however, information about treatment is currently lacking. This study included dogs with a presumptive or definitive diagnosis of an aortic body chemodectoma that underwent treatment with toceranib phosphate. Cases were solicited via the American College of Veterinary Internal Medicine Cardiology, Internal Medicine, and Oncology listservs using an electronic survey. Cox multivariate analysis of factors potentially impacting survival time was completed. Twenty-seven (27) cases were included in analysis. The clinical benefit rate (complete remission, partial remission, or stable disease >10 weeks) was 89%. A median survival time of 478 days was found for those receiving toceranib alone (n = 14), which was not statistically different from those treated with additional modalities (521 days). No factors evaluated statistically impacted outcome. Further, prospective studies are warranted to evaluate the use of toceranib for the treatment of canine aortic body chemodectomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|